The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 36, No. 10, pp. 1567-1576. DOI 10.1345/aph.1C027
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zillich, A.
Right arrow Articles by Carter, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zillich, A.
Right arrow Articles by Carter, B.

Research Articles

Eplerenone--a novel selective aldosterone blocker

AJ Zillich and BL Carter

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of eplerenone, a new selective aldosterone blocker. DATA SOURCES: Primary literature and review articles were obtained via MEDLINE search (1966-April 2002). Additional studies and abstracts were identified from the bibliographies of reviewed literature. STUDY SELECTION AND DATA EXTRACTION: Studies and review articles related to eplerenone, aldosterone, aldosterone antagonist, and spironolactone were reviewed. Data pertinent to this article were included. DATA SYNTHESIS: Eplerenone is a selective aldosterone blocker. Recent data have demonstrated the deleterious effects of aldosterone in several chronic disease states including hypertension and heart failure. Animal studies using eplerenone have shown a positive role for aldosterone antagonism in the treatment of hypertension, heart failure, myocardial infarction, renal disease, and atherosclerosis. In humans, eplerenone appears to be effective for the treatment of hypertension. An ongoing study will examine the effect of eplerenone for heart failure. To date, the incidence of adverse effects with eplerenone has been slightly lower than with spironolactone. CONCLUSIONS: Eplerenone appears to be a promising drug in a new class of agents called selective aldosterone blockers. The drug may be approved for treatment of hypertension in 2002. Additional studies are ongoing that may provide information on other clinical uses for this medication.


This article has been cited by other articles:


Home page
 RadioGraphicsHome page
S. M. Patel, R. K. Lingam, T. I. Beaconsfield, T. L. Tran, and B. Brown
Role of Radiology in the Management of Primary Aldosteronism
RadioGraphics, July 1, 2007; 27(4): 1145 - 1157.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J. Zhang, F. T F Tsai, and D. S Geller
Differential interaction of RU486 with the progesterone and glucocorticoid receptors.
J. Mol. Endocrinol., August 1, 2006; 37(1): 163 - 173.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
B. J Barnes and P. A Howard
Eplerenone: A Selective Aldosterone Receptor Antagonist for Patients with Heart Failure
Ann. Pharmacother., January 1, 2005; 39(1): 68 - 76.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
W. F. Young Jr.
Minireview: Primary Aldosteronism--Changing Concepts in Diagnosis and Treatment
Endocrinology, June 1, 2003; 144(6): 2208 - 2213.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.